Analysts Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) Price Target at $7.83

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have been assigned an average rating of “Buy” from the seven research firms that are covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $7.83.

AQST has been the subject of several analyst reports. Leerink Partnrs upgraded Aquestive Therapeutics to a “strong-buy” rating in a research note on Friday, May 10th. SVB Leerink initiated coverage on Aquestive Therapeutics in a research note on Friday, May 10th. They set an “outperform” rating and a $8.00 price target for the company. Piper Sandler initiated coverage on Aquestive Therapeutics in a research note on Thursday, April 11th. They set an “overweight” rating and a $10.00 price target for the company. JMP Securities restated a “market outperform” rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research note on Wednesday, June 26th. Finally, HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research note on Friday, July 26th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. SG Americas Securities LLC purchased a new position in shares of Aquestive Therapeutics in the first quarter valued at $54,000. Jump Financial LLC acquired a new stake in shares of Aquestive Therapeutics during the fourth quarter valued at $60,000. Financial Advocates Investment Management boosted its stake in shares of Aquestive Therapeutics by 70.0% during the second quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock valued at $88,000 after acquiring an additional 14,000 shares during the last quarter. Lazard Asset Management LLC boosted its stake in shares of Aquestive Therapeutics by 115.5% during the first quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock valued at $124,000 after acquiring an additional 15,601 shares during the last quarter. Finally, PFG Investments LLC acquired a new stake in shares of Aquestive Therapeutics during the first quarter valued at $204,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Trading Down 0.5 %

AQST stock opened at $3.80 on Wednesday. The company has a market capitalization of $345.95 million, a P/E ratio of -9.05 and a beta of 2.81. Aquestive Therapeutics has a twelve month low of $1.25 and a twelve month high of $6.23. The business has a 50 day simple moving average of $2.86 and a 200-day simple moving average of $3.32.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.08). The firm had revenue of $12.05 million during the quarter, compared to analyst estimates of $12.22 million. During the same period in the prior year, the firm earned $0.11 earnings per share. Research analysts predict that Aquestive Therapeutics will post -0.49 EPS for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.